Compare YEXT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YEXT | DCTH |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 644.4M | 578.4M |
| IPO Year | 2017 | 2015 |
| Metric | YEXT | DCTH |
|---|---|---|
| Price | $7.39 | $14.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $24.00 |
| AVG Volume (30 Days) | ★ 655.9K | 253.4K |
| Earning Date | 12-07-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | 107.53 |
| EPS | ★ 0.15 | 0.04 |
| Revenue | ★ $170,201,000.00 | N/A |
| Revenue This Year | N/A | $24.61 |
| Revenue Next Year | $1.04 | $24.27 |
| P/E Ratio | ★ $48.87 | $360.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.27 | $8.12 |
| 52 Week High | $9.03 | $17.42 |
| Indicator | YEXT | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 69.53 | 41.02 |
| Support Level | $6.04 | $14.00 |
| Resistance Level | $7.91 | $16.51 |
| Average True Range (ATR) | 0.22 | 0.49 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 97.89 | 26.92 |
Yext Inc provides a knowledge engine platform that lets businesses manage their digital knowledge in the cloud and sync it to approximately 200 services including Apple Maps, Bing, Cortana, Facebook, Google, Google Maps, Instagram, Siri and Yelp. Digital knowledge is the structured information that a business wants to make publicly accessible. The company also makes search intelligent by helping to provide precise, accurate and current answers to location-based queries that are conducted across the web and mobile applications and voice and artificial intelligence, or AI, engines. The company derives the majority of its revenues from subscription services. Geographically, the company generates a majority of its revenue from North America and the rest from International markets.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.